RxDoctor Payments Data

Lisa Capaldini, MD

Internal Medicine · San Francisco, CANPI 1841249240

Payments from drug & device makers

$433,727in general payments, 2019–2025

Across 1,066 payments — averaging $406.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$338K
  • Gilead$86K
  • Merck$6K
  • Theratechnologies Inc.$1K
  • Johnson & Johnson$732
  • Roche Diagnostics Corporation$436
  • plus $1K from 8 others

What the payments were for

  • Consulting fees$82,54619%
  • Speaking & faculty fees$287,59566%
  • Travel & lodging$41,38410%
  • Food & beverage$21,8275%
  • Education$3740%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$433,727 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$138,339
Medicare patients
251
Services billed
1,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine318$1,011,530
BiktarvyBictegrav/Emtricit/Tenofov Ala163$682,399
JulucaDolutegravir/Rilpivirine125$449,989
TivicayDolutegravir Sodium126$351,608
TriumeqAbacavir/Dolutegravir/Lamivudi63$279,295
SerostimSomatropin13$262,784
DescovyEmtricitabine/Tenofov Alafenam79$180,549
PifeltroDoravirine86$151,314
PrezcobixDarunavir/Cobicistat50$119,266
OdefseyEmtricitab/Rilpiviri/Tenof Ala17$88,029
EliquisApixaban106$87,175
IsentressRaltegravir Potassium34$66,884
Maraviroc52$59,482
EdurantRilpivirine Hcl39$58,824
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$48,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Juluca, Tivicay, Triumeq$337,816$2,092,422632 claims
GileadBiktarvy, Descovy, Genvoya$86,208$910,972254 claims
MerckPifeltro, Isentress, Delstrigo, Januvia$5,989$262,513150 claims
Johnson & JohnsonPrezcobix$732$119,26650 claims
Janssen Scientific Affairs, LLCEdurant$216$58,82439 claims
Novo NordiskOzempic$109$24,20413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →